Artiva Biotherapeutics' (ARTV) Outperform Rating Reaffirmed at Wedbush

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report)'s stock had its "outperform" rating restated by equities researchers at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They currently have a $18.00 price target on the stock. Wedbush's price objective would indicate a potential upside of 469.62% from the company's current price. Wedbush also issued estimates for Artiva Biotherapeutics' Q1 2025 earnings at ($0.62) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.54) EPS, FY2026 earnings at ($2.68) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.95) EPS.

Several other research firms have also commented on ARTV. Needham & Company LLC restated a "buy" rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Tuesday. HC Wainwright began coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They set a "buy" rating and a $20.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $20.40.

Artiva Biotherapeutics Trading Down 10.7 %

Artiva Biotherapeutics stock traded down $0.38 during mid-day trading on Tuesday, hitting $3.16. The company had a trading volume of 80,335 shares, compared to its average volume of 114,168. The company's fifty day moving average is $4.71 and its 200-day moving average is $9.23. Artiva Biotherapeutics has a 12-month low of $3.15 and a 12-month high of $17.31.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $152,234,000. Franklin Resources Inc. acquired a new position in Artiva Biotherapeutics in the 3rd quarter valued at $7,435,000. Geode Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth $4,774,000. Samsara BioCapital LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $4,506,000. Finally, Wellington Management Group LLP purchased a new position in shares of Artiva Biotherapeutics in the third quarter worth about $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.